Adverse events430

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 430

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nasopharyngitis	Infections and infestations	Treatment Arm 1: OKZ 64 mg q4w + MTX	71	1,043	90
other	Nasopharyngitis	Infections and infestations	Treatment Arm 2: OKZ 64 mg q2w + MTX	87	1,061	108
other	Upper respiratory tract infection	Infections and infestations	Treatment Arm 1: OKZ 64 mg q4w + MTX	59	1,043	70
other	Upper respiratory tract infection	Infections and infestations	Treatment Arm 2: OKZ 64 mg q2w + MTX	67	1,061	84
other	Bronchitis	Infections and infestations	Treatment Arm 1: OKZ 64 mg q4w + MTX	59	1,043	66
other	Bronchitis	Infections and infestations	Treatment Arm 2: OKZ 64 mg q2w + MTX	45	1,061	51
other	Alanine aminotransferase increased	Investigations	Treatment Arm 1: OKZ 64 mg q4w + MTX	95	1,043	156
other	Alanine aminotransferase increased	Investigations	Treatment Arm 2: OKZ 64 mg q2w + MTX	115	1,061	194
other	Aspartate aminotransferase increased	Investigations	Treatment Arm 1: OKZ 64 mg q4w + MTX	52	1,043	80
other	Aspartate aminotransferase increased	Investigations	Treatment Arm 2: OKZ 64 mg q2w + MTX	63	1,061	94
other	Leukopenia	Blood and lymphatic system disorders	Treatment Arm 1: OKZ 64 mg q4w + MTX	46	1,043	66
other	Leukopenia	Blood and lymphatic system disorders	Treatment Arm 2: OKZ 64 mg q2w + MTX	60	1,061	95
other	Neutropenia	Blood and lymphatic system disorders	Treatment Arm 1: OKZ 64 mg q4w + MTX	42	1,043	79
other	Neutropenia	Blood and lymphatic system disorders	Treatment Arm 2: OKZ 64 mg q2w + MTX	57	1,061	92
other	Lymphopenia	Blood and lymphatic system disorders	Treatment Arm 1: OKZ 64 mg q4w + MTX	41	1,043	62
other	Lymphopenia	Blood and lymphatic system disorders	Treatment Arm 2: OKZ 64 mg q2w + MTX	50	1,061	90
other	Hypercholesterolaemia	Metabolism and nutrition disorders	Treatment Arm 1: OKZ 64 mg q4w + MTX	25	1,043	25
other	Hypercholesterolaemia	Metabolism and nutrition disorders	Treatment Arm 2: OKZ 64 mg q2w + MTX	42	1,061	44
other	Hypertension	Vascular disorders	Treatment Arm 1: OKZ 64 mg q4w + MTX	32	1,043	33
other	Hypertension	Vascular disorders	Treatment Arm 2: OKZ 64 mg q2w + MTX	44	1,061	49

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03120949/events

API reference For AI assistants

Adverse events430

Sources 3

Read this list from software.